Bcl-xL is an oncogenic driver in colorectal cancer
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is the second most common malignant neoplasia in women and men worldwide. The B-cell lymphoma 2 (Bcl-2) protein family is mainly known for its pivotal role in the regulation of the mitochondrial death pathway. Anti-apoptotic Bcl-2 proteins may provide survival benefits and induce therapy resistance in cancer cells. Among anti-apoptotic Bcl-2 proteins, we found solely Bcl-x L strongly upregulated in human CRC specimens. In order to study protein function in the context of tumor initiation and progression in vivo, we generated a mouse model lacking Bcl-x L in intestinal epithelial cells (Bcl-x LIEC-KO). If challenged in an inflammation-driven tumor model, Bcl-x LIEC-KO mice showed a significantly reduced tumor burden with lower tumor numbers per animal and decreased tumor sizes. Analysis of cell death events by immunohistochemistry and immunoblotting revealed a striking increase of apoptosis in Bcl-x L-negative tumors. qRT-PCR and immunohistochemistry excluded changes in proliferative capacity and immune cell infiltration as reasons for the reduced tumor load and thereby identify apoptosis as key mechanism. Human CRC tissue was cultured ex vivo and treated with the small molecule compound ABT-737, which inhibits Bcl-x L and Bcl-2. Under ABT-737 treatment, the amount of apoptotic tumor cells significantly increased compared with controls, whereas proliferation levels remained unaltered. In summary, our findings identify Bcl-x L as a driver in colorectal tumorigenesis and cancer progression, making it a valuable target for clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032 · cited 1×
“Due to the activity of BH3-only proteins like PUMA and NOXA, pro-apoptotic proteins get released from their binding, leading to subsequent mitochondrial activation and initiation of the downstream apoptosis cascade.(3) Anti-apoptotic proteins are overexpressed in different tumor entities, supporting cell death avoidan…”
BackgroundZaanan, A., Okamoto, K., Kawakami, H., Khazaie, K., Huang, S., & Sinicrope, F. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657833 · Cited by 59
Cited by
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Self-citationAzwar, S., Seow, H. F., Abdullah, M., Faisal Jabar, M., & Mohtarrudin, N. (2021) · Biology · doi:10.3390/biology10090854 · Cited by 173
AbouAitah, K., Hassan, H. A., Swiderska-Sroda, A., Gohar, L., Shaker, O. G., Wojnarowicz, J., Opalinska, A., Smalc-Koziorowska, J., Gierlotka, S., & Lojkowski, W. (2020) · Cancers · doi:10.3390/cancers12010144 · Cited by 105
“BCL-2 is classified as an anti-apoptotic protein in many cancers, including colorectal cancer [61,62], inducing cancer resistance to drugs.”
BackgroundMicroRNAs and colorectal cancer chemoresistance: New solution for old problem
Vaghari-Tabari, M., Majidinia, M., Moein, S., Qujeq, D., Asemi, Z., Alemi, F., Mohamadzadeh, R., Targhazeh, N., Safa, A., & Yousefi, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118255 · Cited by 58
BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer
Ramesh, P., Lannagan, T. R. M., Jackstadt, R., Atencia Taboada, L., Lansu, N., Wirapati, P., van Hooff, S. R., Dekker, D., Pritchard, J., Kirov, A. B., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00816-w · Cited by 52
Metadata
- Authors
- Scherr, A.-L., Gdynia, G., Salou, M., Radhakrishnan, P., Duglova, K., Heller, A., Keim, S., Kautz, N., Jassowicz, A., Elssner, C., He, Y.-W., Jaeger, D., Heikenwalder, M., Schneider, M., Weber, A., Roth, W., Schulze-Bergkamen, H., & Koehler, B. C.
- Venue
- Cell Death & Disease
- Published
- 2016-08-18
- Volume
- 7
- Issue
- 8
- Pages
- e2342-e2342
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2507230123
- Cited by
- 107
- References
- 2
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bcl-xL is an oncogenic driver in colorectal cancer. https://app.cochat.ai/papers/10.1038/cddis.2016.233
- The paper
- Scherr, A.-L., Gdynia, G., Salou, M., Radhakrishnan, P., Duglova, K., Heller, A., Keim, S., Kautz, N., Jassowicz, A., Elssner, C., He, Y.-W., Jaeger, D., Heikenwalder, M., Schneider, M., Weber, A., Roth, W., Schulze-Bergkamen, H., & Koehler, B. C. (2016). Bcl-xL is an oncogenic driver in colorectal cancer. Cell Death & Disease. https://doi.org/10.1038/cddis.2016.233
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.